Tadalafil Tablet, Film Coated
Product Images NDC 71335-2583

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-2583). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 01)

Chemical structure of tadalafil showing its molecular framework with fused rings, including an indole moiety and other characteristic features consistent with this active ingredient.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 02)

A figure with four line graphs showing the difference in blood pressure measurements (systolic and diastolic) between tadalafil and placebo over time in hours. The charts include Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP, each plotting changes up to 96 hours post-administration.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 03)

A chart depicting the changes in systolic blood pressure over 24 hours post-dose with two treatments: tadalafil 20 mg combined with doxazosin 8 mg, and placebo combined with doxazosin 8 mg. The top graph shows standing systolic blood pressure changes, while the bottom graph shows supine systolic blood pressure changes, both plotted over time in hours.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 04)

Line graph showing the effect on systolic blood pressure (mmHg) over 12 hours after administration of 20 mg tadalafil or placebo, combined with 8 mg once daily doxazosin, measured at 08:00 and 20:00 time points. The graph compares changes in blood pressure between tadalafil and placebo groups over time.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 05)

A pharmacokinetic concentration-time curve showing plasma tadalafil concentrations (μg/L) over time (hours) after different dosing regimens: a single 20 mg dose, a single 5 mg dose, and once-daily 5 mg dosing following 5 consecutive days of administration. The graph includes error bars indicating variability at each time point.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 06)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment between tadalafil 5 mg and placebo. The x-axis represents duration of treatment in weeks (0, 4, 8, 12), and the y-axis shows change from baseline in IPSS total score, with more negative values indicating greater improvement. The graph shows greater improvement with tadalafil 5 mg compared to placebo, with statistically significant differences (p<0.01) indicated at 12 weeks.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 07)

Line graph depicting the change from baseline in IPSS Total Score over 12 weeks of treatment comparing tadalafil 5 mg and placebo. The x-axis represents the duration of treatment in weeks (0, 1, 4, 8, 12), and the y-axis shows the change from baseline in IPSS Total Score, with lower scores indicating improvement. The tadalafil 5 mg group shows a greater reduction over time compared to placebo, with statistical significance markers at certain points (p < 0.01).*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 08)

A line graph showing least-squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride versus Placebo/Finasteride. The graph plots LS mean change on the vertical axis and weeks of therapy (0, 4, 12, 26) on the horizontal axis, with Tadalafil/Finasteride consistently showing greater reduction than placebo.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 09)

A line graph comparing change from baseline in IPSS total score over treatment duration (weeks) between Tadalafil 5 mg and placebo groups. The x-axis represents treatment duration in weeks (0 to 12), and the y-axis shows change from baseline in IPSS score. Tadalafil shows a steeper decrease in scores over time compared to placebo, indicating greater symptom improvement.*

FDA Label Image

Unichem Logo (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 10)

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 11)

FDA Label Image

Label (Lbl713352583)

Label for tadalafil tablets, USP 20 mg oral film-coated tablets. The package contains 30 tablets and is labeled Rx only. It is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Unichem Laboratories Ltd. The label includes storage and dosage instructions, warnings, and both 2D and linear barcodes alongside the NDC 71335-2583-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.